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Abstract Osteoporosis is accompanied by predominantly
metaphyseal fractures with a delayed and qualitatively
reduced healing process. This study addressed the question
of whether fracture healing in the context of osteoporosis
prophylaxis is improved with estrogen (E) or alendronate
(ALN). Thirty-six ovariectomized and 12 sham-operated
12-week-old rats received soy-free (osteoporotic C, sham),
E-, or ALN- supplemented diets. After 10 weeks, a meta-
physeal tibia osteotomy and standardized T-plate ﬁxation
were performed. After a 5-week healing process, the
fracture callus was evaluated qualitatively by biomechan-
ical bending test and quantitatively in microradiographic
sections. The time course of callus formation was exam-
ined using ﬂuorochrome-labeled histological sections.
Administration of E improved the biomechanical proper-
ties of callus (stiffness [N/mm]: sham: 110.2 ± 76.07, C:
41.28 ± 33.70, E: 85.72 ± 47.24, ALN: 72.07 ± 34.68).
The resistance to microfracturing seen in E-treated animals
was signiﬁcantly enhanced and even superior to sham
(yield load [N] sham: 27.44 ± 9.72, C: 21.04 ± 12.47, E:
42.85 ± 13.74
D, ALN: 25.28 ± 6.4
)( *P\0.05 vs. sham
group,
D P\0.05 vs. C group,
• P\0.05 vs. E group).
Trabecular bone in particular was improved, indicating the
presence of physiological endosteal bridging (Tr.Dn [%]
sham: 10.53 ± 18.9, C: 1.01 ± 0.14, E: 24.13 ± 34.09
D,
ALN: 3.99 ± 8.3
). ALN did not help bone healing, as
shown by mechanical tests. Compared to the C group,
statistically, ALN did not show worse properties. The
induction of callus formation under ALN treatment was
slightly delayed (Tt.Cl [mm
2] sham: 3.68 ± 0.66, C:
3.44 ± 0.42, E: 3.69 ± 0.58, ALN: 3.06 ± 0.56). Osteo-
porotic metaphyseal fracture healing was qualitatively and
quantitatively improved by E prophylaxis. The process of
fracture healing occurred nearly physiologically (sham-
like). Notably, ALN hardly improved metaphyseal callus
properties when assessed as osteoporosis prophylaxis, but
to a lesser extent than E.
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Life expectancy has recently increased, resulting in
changing population demographics. As the population
ages, osteoporosis is becoming one of the most prominent
worldwide health problems. Menopause involves hor-
monal changes that increase bone turnover and distort the
balance between bone formation and bone resorption [1].
Hormone deﬁciency impairs cancellous metaphyseal
bone, which reduces bone mineral density (BMD) in
humans and animals [2–4]. Within the metaphysis, the
trabecular structure degrades. Bone loss occurs in the
diaphyseal bone as well, but to a lesser extent [5]. The
mechanical strength of cortical bone is preserved as a
result of periosteal apposition [4]. Therefore, long bones
are more often predisposed to osteoporotic fractures at the
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time risk in the United States for a hip, spine, or forearm
fracture at the age of 50 years has been estimated to be
40% in women and 13% in men [7]; overall reduction in
survival due to osteoporotic hip fractures is approximately
15% [8]. In osteoporotic organisms, the fracture healing
process is delayed and poor in quality [9, 10]. Especially
in humans, postmenopausal osteoporosis negatively
affects the fracture healing process [11], and the recovery
of functional competence is delayed [12].
Treatment with estrogen (17-b-E), selective estrogen
receptor modulators (SERMs), or bisphosphonates has
been shown to improve postmenopausal osteoporotic bone
[13]. Estrogen (E) therapy, such as hormone replacement
therapy (HRT), was aborted during the Women’s Health
Initiative hormone trial because of the increased incidence
of breast cancer, thromboembolic events and stroke, and
cardiovascular disease [14]. However, recently, more
detailed analyses have shown that HRT can be beneﬁcial
without increasing the risk of these conditions when initi-
ated in early menopausal women. Additionally, selection of
the appropriate dose and application method can also
reduce the risks associated with HRT [15].
Bisphosphonate alendronate (ALN) is applied as an
antiresorptive treatment that induces the formation of a
large callus with high bone mineral content. Such struc-
tures have, until now, been examined mostly in diaphy-
seal fractures [16]. As an osteoclast inhibitor, it delays
callus remodeling, so that diaphyseal fractures are healed
with large amounts of imperfect, woven bone material
[16, 17]. Nitrogen-containing ALN inhibits osteoclast-
mediated bone resorption through inhibition of the mev-
alonate pathway and impairment of intracellular vesicle
transport. Its effects are not related to a decrease in
osteoclast number, and apoptosis occurs only as a sec-
ondary phenomenon [18]. Bisphosphonates are widely
recognized as effective agents to increase bone mass and
reduce fracture risk in primary and secondary osteoporo-
sis [19–22]. Notably, bisphosphonates enhance BMD in
the affected extremities during fracture healing [23, 24].
However, a decrease in tissue heterogeneity, characterized
by alterations in the distribution of BMD, mineral crystal
composition, and collagen maturity, has been observed
under ALN treatment, and this could affect bone strength
[25].
In the present study, E and ALN were applied in
ovariectomized rats for osteoporosis prophylaxis and tested
for their effects on the fracture healing process. The met-
aphyseal fracture model was chosen because osteoporotic
fractures affect mainly metaphyseal cancellous bone. The
study design allowed us to examine the osteoporotic frac-
tures that occurred during osteoporosis prophylaxis with E
and ALN.
Materials and Methods
Animals and Treatment Groups
Thirty-six 12-week-old female Sprague Dawley rats
(Winkelmann, Borken, Germany) were ovariectomized,
and 12 control rats underwent sham operation under
xylazine (Rompun, Bayer Health Care) and ketamine
(Ketanest S, Pﬁzer Pharma) (3.5 v/v, 1 ml/kg) anesthesia.
After surgery, ovariectomized rats were divided in three
groups, each containing 12 animals. The ﬁrst group (C) and
the sham-operated group were fed phytoestrogen-free pel-
leted food (Ssniff SM R/M, 10-mm pellets; Ssniff Spezi-
alita ¨ten GmbH, Soest, Germany). The third group (E)
received phytoestrogen-free food supplemented with 17-b-
estradiol (Sigma Medical, Apeldoorn, The Netherlands).
The average daily intake was 0.086 g. In the fourth group,
phytoestrogen-free food was supplemented with ALN
(10 mg/kg, Merck & Co., Whitehouse Station, NJ). This
group was subjected to an average intake of 0.17 mg/d.
The substances were applied in established oral doses [17,
26, 27]. After 10 weeks, during which the ovariectomized
animals developed osteoporosis [28], all animals under-
went a newly developed bilateral proximal metaphyseal
osteotomy and osteosynthesis, which was performed with a
ﬁve-hole T-shaped titanium plate (XS 57-05140, Stryker
Trauma, Selzach, Switzerland) bridging technique [29].
The treatment with speciﬁc diets was continued up to
35 days.
The animal study protocol was approved by the local
regional government and conformed to German animal
protection laws (District Government of Braunschweig,
permission from 12/05/03, Az: 509.42502/01-53.03).
Intravital Fluorochrome Labeling
To visualize the location, amount, and time course of
newly built bone tissue, we subcutaneously injected ﬂuo-
rochrome stains, which bind competitively to the calcium
on the surface of hydroxylapatite in newly built bone
(Merck, Darmstadt, Germany) [30]. The stains used
included xylenol (orange, 90 mg/kg) on day 13, calcein
(green, 10 mg/kg) on day 18, alizarin (red, 30 mg/kg) on
days 24 and 26, and tetracycline (yellow, 25 mg/kg) on day
35. The additional dose of alizarin red was provided on day
26 to intensify the color.
Preparation of the Tibiae
The animals were decapitated while under deep CO2
anesthesia on day 35. Tibiae were prepared; the skin,
muscles, and tendons of the lower leg were removed
accurately. Exarticulation of the tibia–ﬁbula complex in the
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removed. Tibiae were immediately stored in plastic tubes
at -20 C until further analysis.
Radiographic Evaluation and Mechanical Testing
Microfocus radiographs were taken in the anteroposterior
and mediolateral views, and fracture healing of each
osteosynthesis was evaluated in a blinded manner. In par-
ticular, the position of the implants, accidental fracturing of
the ﬁbula, and axial deviation were examined.
A standardized three-point bending and breaking test
device (Zwick Software, Bensheim, Germany) was used to
examine the biomechanical properties of the callus area,
including stiffness (S) and yield load, as previously
described [31]. The stamp of the test device was driven
down with a speed of feet motion of 50 mm/min. The force
(N) was plotted against the distance of tibial bending (mm).
This curve shows a linear progression in the ﬁrst phase,
which represents the stiffness of the bone. In the second
part of the curve, the magnitude of this positive slope
declines; elasticity changes to irreversible plastic defor-
mation. The onset of curve declination is the force of ﬁrst
microfracturing (yield load).
Preparation for Microscopy and Microradiography
Tibiae were defatted and embedded in methylmethacrylate.
By means of a standardized cutting technique, the three
central sections of the metaphyseal fracture region from the
level of the eminentia intercondylaris were used for
microscopic evaluation and microradiographed for quanti-
tative analyses. Microradiography was performed as pre-
viously described [32]. A light microscope (Leitz DM-
RXE, Leica, Bensheim, Germany) with an I3 ﬁlter system
(excitation ﬁlter 450–490 nm, dichronic mirror 510 nm,
suppression ﬁlter 515 nm) was used. The different ﬂuoro-
chrome-labeled areas were evaluated with the transmitted
and incident light objective (PL Fluotar 10/0.30). Histo-
logical sections and microradiographic images were
assessed with a digital camera (Leica DC200) and the
Quantimet digital image processing system (Leica DM-
RXE, Bensheim, Germany).
Evaluation and Statistics
In the microradiographs, callus density (amount of calciﬁed
tissue per mm
2/callus area) and the callus width (mean
width measured by 10 parallel lines placed perpendicularly
to cortical bone) as well as cortical structure (density and
width) and trabecular bone parameters (density, width, and
number of nodes) were determined digitally. Data are
shown as the means of three microradiographic sections
(Fig. 5). For the intravital ﬂuorochrome–labeled histolog-
ical sections, the same areas were evaluated to determine
the amount of bound calcein (green), alizarin (red), and
tetracycline (yellow) labeling by the Quantimet digital
image processing system (Fig. 5)[ 32]. It was not possible
to visually distinguish the xylenol (orange) because only a
small island of xylenol-labeled bone could be found, and
this was surrounded by intensely green, calcein-labeled
bone. In addition, the total callus area was calculated. The
ASBMR Nomenclature Committee [33] was followed for
all abbreviations.
For statistical analysis of the data, the mean values and
standard deviations for each parameter were calculated.
Differences between the four tested groups were assessed
by one-way analysis of variance and Tukey-Kramer post
hoc tests (Prism, GraphPad, San Diego, CA). P values of
\0.05 were considered to be signiﬁcant.
Fig. 1 Biomechanical testing of callus formation. Stiffness was not
signiﬁcantly enhanced in the estrogen (E)-treated group; changes in
the alendronate (ALN)-treated group did not reach sham values. Yield
load in the E group was signiﬁcantly improved compared to the
osteoporotic C (C) group, and superior to sham group. The ALN
group was slightly enhanced compared to C. P values of\0.05 were
considered to be signiﬁcant (* P\0.05 vs. sham,
D P\0.05 vs. C,
• P\0.05 vs. E)
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Body Weight
After ovariectomy, body weight increased signiﬁcantly in
the C and ALN groups compared to the sham and E groups.
At the time of osteotomy body weight (g) was: sham,
276.5 ± 19.2; C, 343.3 ± 23.89*; E, 255.5 ± 20.46;
ALN, 341.4 ± 11.98* (* P\0.05 vs. sham group). In the
second part of the trial, after the osteotomy procedure, no
further changes in body weight were observed.
Radiographic Evaluation
The tibial osteotomies of all 48 rats healed adequately,
without implant loosening. In six rats (two each in the
sham, C, and E groups), accidental fracturing of the ﬁbula
occurred (probably during internal ﬁxation). Tibiae healed
with axial deviation of more than 30 degrees and more
visible callus formation. This biomechanical factor con-
founded the fracture healing process, interfering with the
effects of the administered test substances. Thus, these
animals were excluded from the analyses.
Biomechanical Testing
The yield load after E treatment was signiﬁcantly enhanced
compared to the control group and was superior to that
observed in the sham group. After ALN treatment, S and
yield load were slightly but not signiﬁcantly improved
compared to levels observed in the C group. However,
yield load was signiﬁcantly lower than in the E group. The
Table 1 Quantitative evaluation of microradiographic sections of the tibial callus formation in osteoporotic rats
a
Microradiography Sham C E ALN
Mean SD Mean SD Mean SD Mean SD
Cortical width ventromedial (Ct.Wi.v) (mm) 0.29 ±0.14 0.32 ±0.1 0.33 ±0.11 0.34 ±0.12
Cortical width dorsal (Ct.Wi.d) (mm) 0.37 ±0.09 0.31 ±0.1 0.3* ±0.08 0.29* ±0.06
Cortical density ventromedial (Ct.Wi.v) (%) 89.28 ±3.89 98.46 ±1.31 99.13 ±1.07 98.11 ±2.07
Cortical density dorsal (Ct.Wi.d) (%) 98.33 ±2.05 97.42 ±2.1 98.14 ±2.075 97.41 ±2.85
Callus width ventromedial (Cl.Wi.v) (mm) 0.55 ±0.28 0.58 ±0.29 0.51 ±0.24 0.59 ±0.29
Callus width dorsal (Cl.Wi.d) (mm) 0.44 ±0.34 0.44 ±0.24 0.39 ±0.16 0.27 ±0.17
Callus density dorsal (Cl.Dn.d) (%) 63.91 ±29.75 55.74 ±28.86 69.91 ±18.85 55.95 ±23.61
Trabecular width (Tr.Wi) (lm) 2.11 ±1.84 0.97 ±0.07 3.07
D ±2.9 1.5
• ±1.21
C osteoporotic C, E estrogen, ALN alendronate
a Average value ± SD of the mean. P values of\0.05 were considered to be signiﬁcant (* P\0.05 vs. sham group,
D P\0.05 vs. C group,
• P\0.05 vs. E group)
Fig. 2 Quantitative evaluation
of microradiographic sections.
Trabecular structure was
signiﬁcantly enhanced in the
estrogen (E)-treated group
compared to the osteoporotic C
(C) group, surpassing levels
observed in the sham group.
Alendronate (ALN) was slightly
improved compared to C. Callus
density was enhanced under E
treatment and less under ALN
supplementation. P values of
\0.05 were considered to be
signiﬁcant (* P\0.05 vs.
sham,
D P\0.05 vs. C,
• P\0.05 vs. E)
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123stiffness of the three ovariectomized groups was less than
that of the sham group, but this trend was not signiﬁcant
(Fig. 1).
Microradiographic Evaluation
Ventromedial callus width (Cl.Wi.v) did not differ sig-
niﬁcantly between the groups. Its density (Cl.Dn.v) was
improved in the E-treated group (P\0.05 vs. C) and did
not differ from values observed in the sham group.
Dorsal callus width (Cl.Wi.d) in the ALN group was
lower compared to that in other groups; however, this
trend was not signiﬁcant. Although the differences were
not signiﬁcant, the dorsal callus density (Cl.Dn.d) was
again low in ALN and C, compared to E, while group E
reached values similar to that of the sham group. The E
enhanced the endosteal callus density (Cl.Dn.e, P\0.05
vs. ALN). The average trabecular width (Tr.Wi) and
trabecular density (Tr.Dn) were signiﬁcantly greater after
E treatment, compared to the ALN and osteoporotic C
groups. The number of nodes (N.Nd) was signiﬁcantly
enhanced in the E group compared to the osteoporotic C
group, while ALN levels were slightly higher than C
levels. The ventromedial cortical width (Ct.Wi.v) and
density (Ct.Dn.v) showed no signiﬁcant differences
(Table 1). The dorsal cortical width (Ct.Wi.d) was sig-
niﬁcantly thinner in the E and ALN groups, while the
dorsal density (Ct.Dn.d) was comparable in all groups
(Fig. 2; Table 1).
Evaluation of Intravital Fluorochrome Labeling
On the basis of evaluation of the ﬂuorochrome-labeled tibia
sections, E treatment most supported endosteal and dorsal
callus formation (Tt.Cl.d, e, Table 2). The E induced
ventromedial callus formation (Cl.Ar.v) as well; values
were similar to those observed in the sham group. ALN
induced signiﬁcantly less callus formation than was seen in
the E group (Table 2).
During the early period of fracture healing, marked by
calcein green (CG), the E group demonstrated signiﬁ-
cantly more ventromedial callus deposition (Cl.Ar.v)
(Table 2) compared to the C and ALN groups. The early
stage of endosteal callus building (CG Cl.Ar.e) was sig-
niﬁcantly improved by ALN compared to C (Table 2),
although ALN had no effect on ventromedial or dorsal
callus formation. In the next period of the fracture healing
process, labeled by alizarin red, a smaller amount of
callus was formed compared to the CG-labeled early
period. Endosteal (alizarin red Cl.Ar.e) callus formation
was inﬂuenced by E and ALN, but the differences com-
pared to C were not signiﬁcant. In the late fracture
healing phase, labeled by tetracycline, whole callus for-
mation was enhanced compared to the alizarin red–
labeled period, but did not reach the values of the earliest
period (Table 2). Comparing the three phases among all
groups (Figs. 3, 4), there was a reduction of callus
building in the second alizarin red–labeled period in
ventromedial and dorsal areas (P\0.05 vs. CG phase).
Table 2 Time-dependent quantitative analysis of intravital ﬂuorochrome labeling with calcein green (CG, day 18), alizarin red (AK, days 24 and
26), and tetracycline (TC, day 35)
a
Fluochrome labeling Sham C E ALN
Mean SD Mean SD Mean SD Mean SD
Total callus ventromedial (Tt.Cl.v) (mm
2) 0.95 ±0.53 0.71 ±0.35 1.01 ±0.45 0.61
• ±0.39
CG callus area ventromedial (Cl.Ar.v) (mm
2) 0.25 ±0.26 0.16 ±0.12 0.39
D ±0.28 0.14
• ±0.17
AK callus area ventromedial (Cl.Ar.v) (mm
2) 0.09 ±0.11 0.06 ±0.05 0.1 ±0.07 0.1 ±0.09
TC callus area ventromedial (Cl.Ar.v) (mm
2) 0.27 ±0.27 0.13 ±0.12 0.14 ±0.14 0.11* ±0.11
Total callus dorsal (Tt.Cl.d) (mm
2) 1.61 ±0.74 1.52 ±0.1 1.4 ±0.56 1.3 ±0.76
CG callus area dorsal (Cl.Ar.d) (mm
2) 0.5 ±0.21 0.43 ±0.39 0.54 ±0.23 0.52 ±0.37
AK callus area dorsal (Cl.Ar.d) (mm
2) 0.21 ±0.27 0.17 ±0.2 0.11 ±0.06 0.16 ±0.11
TC callus area dorsal (Cl.Ar.d) (mm
2) 0.41 ±0.29 0.22 ±0.23 0.33 ±0.38 0.2 ±0.23
Total callus endosteal (Tt.Cl.e) (mm
2) 1.12 ±0.7 1.21 ±0.8 1.28 ±0.73 1.15 ±0.52
CG callus area endosteal (Cl.Ar.e) (mm
2) 0.35 ±0.29 0.14 ±0.15 0.34 ±0.23 0.35
D ±0.26
AK callus area endosteal (Cl.Ar.e) (mm
2) 0.09 ±0.08 0.14 ±0.12 0.2 ±0.16 0.2 ±0.16
TC callus area endosteal (Cl.Ar.e) (mm
2) 0.34 ±0.36 0.41 ±0.26 0.3 ±0.32 0.2 ±0.22
C osteoporotic C, E estrogen, ALN alendronate
a Average value ± SD of the mean. P values of\0.05 were considered to be signiﬁcant (* P\0.05 vs. sham group,
D P\0.05 vs. C group,
• P\0.05 vs. E group)
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group was signiﬁcantly reduced during the alizarin red
and tetracycline phases compared to the CG period.
Discussion
Osteoporosis is a major health problem and is accompanied
by skeletal fragility and increased fracture risk, especially
metaphyseal fractures [3]. The healing of postmenopausal
osteoporotic fractures is delayed and quantitatively reduced
compared to the rates in normal subjects [9–12, 34]. Thus,
treatments that improve the osteoporotic fracture healing
process are needed.
Previous experimental studies on fracture healing in
osteoporosis have, for the most part, examined the diaph-
yseal femur [16, 35] or tibia [36]. Studies addressing
metaphyseal bone healing have been performed in rats as a
pullout trial [37], in sheep using partial osteotomy [6], and
in rabbits using defect healing [38], or in the context of
varying biomechanical stability [39]. Research on fracture
healing in osteoporosis should be performed predominantly
at the metaphyseal bone because osteoporosis most
strongly affects the metaphyseal cancellous bone [2, 6, 28].
Additionally, diaphyseal bone heals primarily with peri-
osteal callus formation, while metaphyseal bone heals
predominantly endosteally [29]. Therefore, a metaphyseal
osteotomy model was developed [29] in a well-established
rat model of osteoporosis.
The E treatment as an osteoporosis prophylaxis led to
enhanced resistance (yield load, P\0.05 vs. C) and elas-
ticity of the callus (Fig. 1). Trabecular microstructure was
also improved (P\0.05 vs. C) under E treatment (Fig. 2),
but this had no positive effect on the surrounding cortical
bone(Table 1).Regardingthecallusformationrateindorsal
and ventromedial areas, E induced extended callus tissue
formation during the ﬁrst phase of healing, so that the
fracturesitewasstabilizedearly.Withfurthertreatment,less
callus building was necessary (P\0.05 vs. CG phase,
Fig. 3). Endosteally, callus apposition seemed more bal-
anced during all periods, indicating enhancement of the
endosteal healing process. Thus, E-supported fracture
healing occurred ina physiological manner, as evidencedby
the fact that the callus stabilized the bone primarily via
endostealbridging(Fig. 2;Table 1),asistypicalforfracture
healing in healthy metaphyseal bone [29]. The enhanced
callus tissue in the dorsal region also results from the oste-
otomy design. The ventromedial positioning of the bridging
plate and the remaining 0.5-mm osteotomy gap permit mi-
cromovements at the dorsal fracture site. This mechanical
stimulus positively affects fracture callus formation.
These ﬁndings suggest that a short treatment course
(during the ﬁrst weeks after an osteoporotic fracture
occurs) might be beneﬁcial in humans. During this limited
treatment period, the positive effects on fracture incidence,
fracture healing, patient mobility, and rehabilitation could
outweigh any potential negative effects associated with
long-term E therapy. This observation is in accordance
Fig. 3 Intravital ﬂuorochrome labeling. Most of the callus was
created during the early, calcein green (CG)-labeled period in
endosteal and dorsal regions. P values of \0.05 were considered to
be signiﬁcant (* value differs signiﬁcantly from CG area of same
group;
D value differs signiﬁcantly from alizarin red area of same
group). The last chart presents the total callus for all stained periods
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ticular, it seems that when initiated in early-menopausal
women and given at the appropriate dose via the appro-
priate application method, E therapy can provide many
beneﬁts without increasing the risk of certain complica-
tions associated with HRT.
Bisphosphonates have been recognized to have positive
effects on BMD and fracture incidence in osteoporotic
bones. They are considered effective, safe, and well tol-
erated, and can increase bone mass and reduce fracture risk
in primary and secondary osteoporosis [19–22]. In this
study, the ALN showed limited ability to improve the
quality and quantity of fracture callus tissue.
In the physiological fracture healing process, a continu-
ous remodeling of the ﬁrst, very elastic, woven bone into
lamellar bone takes place, yielding the biomechanical
properties of cortical bone. The amount of callus formation
was reduced under ALN therapy in comparison to E and
shamgroupsandslightlyimprovedcomparedtotheCgroup.
ThebiomechanicalpropertiesofthecallusintheALNgroup
weresimilartothoseobservedinuntreatedosteoporoticrats.
We expected extensive callus building during ALN treat-
ment [16,17] as a result of the osteoclast-inhibiting effect as
well as the delayed remodeling process, but we did not
observe such a trend. A signiﬁcantly lower mineral apposi-
tion rate, bone formation rate, and mineralizing surface in
Fig. 4 Corresponding
microradiographic and
ﬂuorescence-labeled sections.
Compared to physiological
healing in the sham group,
callus formation in the
osteoporotic C (C) group was
enhanced, but unstructured and
less dense. Estrogen (E)
administration induced less
callus formation, but the callus
present was very compact and
dense, with increased amounts
of trabecular structure. The
alendronate (ALN) group
displayed fewer and
unconstrained calluses and
trabeculas
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already been reported [40]. In that study, a prolongation of
thenaturalfracturehealingprocessduetostrongsuppression
of osteoclastic bone resorption is suggested. Other recent
studies found high binding afﬁnities of ALN for bone
hydroxyapatite,whichaffectsmineraldynamicsandcellular
function within bone [41]. Additionally, bone strength is
affected by the distribution of BMD, mineral crystal com-
position, and collagen maturity [25]. A reason for the
observed callus properties under ALN in this study may be
the delayed initiation of callus building as a result of
impairment on a cellular level. The extensive callus forma-
tion described has been observed in trials with 16 or
26 weeks of fracture healing [16, 17, 40, 42]. The 5-week
duration of this study may have been too brief.
One aspect of the metaphyseal cortical bone in the rat
tibia must be mentioned: as previously described [29, 43]
(Stuermer et al., personal communication), osteoporosis
does not seem to inﬂuence the metaphyseal cortical bone.
Therefore, the investigated substances had no inﬂuence on
the cortical width or the cortical density (Table 1).
The results of this study are presented bearing in mind
the methodological limitations of the work. First, the
design of the study focused on short-term application of the
substances. The fracture healing and biomechanical values
might differ with longer-term E and especially ALN sup-
plementation. In addition, we did not examine all systemic
effects, but rather focused on E substitution. Because of the
presence of E in the sham and in the E-treated groups, body
weight was signiﬁcantly lower than in the ALN and the
osteoporotic control group. This is a well-known systemic
effect of E [2]. The differences in the body weights may
have an inﬂuence on the biomechanical properties of bone,
but this was not factored into the results. This study ana-
lyzed whether ALN and E improve fracture healing in
comparison to untreated osteoporotic bone, and whether
the treatment could achieve results with the quality and
quantity of healthy bone (sham). Therefore, the systemic
effects have to be considered in analysis of all results.
We now know about three-dimensional analyses by
quantitative computed tomography (QCT) or microfocus
computed tomography (lCT) but at the time of this work,
these methods were not yet available.
In summary, osteoporotic metaphyseal fracture healing
is improved by E prophylaxis. The fracture healing process
occurs at a nearly physiological level. The widely used and
Fig. 5 Examples of Quantimet-
based evaluation of
microradiographic (a: native
picture, b cortical structure, c
callus areas, d trabecular
structure) and ﬂuorescence-
labeled sections (a native
picture, b cortical structure, c
calcein green-labeled callus, d
alizarin red–labeled callus, e
tetracycline-labeled callus, f
entire callus area)
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123effective antiosteoporotic ALN negligibly improved met-
aphyseal fracture healing, quantitatively and qualitatively
compared to control group, but did not exhibit E-like
properties. Finally, the metaphyseal tibial osteotomy model
in ovariectomized rats produced reliable results regarding
the therapeutic effects of antiosteoporotic substances.
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